Dr. Mei He
In most cases, the sooner cancer is diagnosed and treated, the better a person's chance for full recovery. Accurate prediction and early diagnosis is critical. The development of early and personalized diagnostic protocols is considered a very promising avenue to decrease mortality from cancer and improve outcome. My research is focused on developing low-cost biomedical devices for point-of-care (POC) cancer diagnostics. POC diagnosis accounts for 2% of the cost of health care, yet can affect 60-70% of treatment decisions, bypassing the need for sophisticated laboratory systems and expanding access to healthcare. Emerging microfluidic-based analyzing platforms could offer high-throughput and high-precision screening with reduced equipment cost and analysis time. My research will translate innovation from microfluidic analysis and biomaterial integration to develop disposable, low-cost, point-of-care devices for sensitive cancer biomarker detection from a finger-prick of blood.